These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 14515884

  • 1. Managing psychotropic drug costs: will formularies work?
    Huskamp HA.
    Health Aff (Millwood); 2003; 22(5):84-96. PubMed ID: 14515884
    [Abstract] [Full Text] [Related]

  • 2. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare.
    Morden NE, Garrison LP.
    Health Aff (Millwood); 2006; 25(2):491-500. PubMed ID: 16522603
    [Abstract] [Full Text] [Related]

  • 3. Dialogue. Prescription for problems? Capitating mental health drugs--the great debate.
    Docherty JP, Browne RA, Farmer M.
    Behav Healthc Tomorrow; 1998 Oct; 7(5):32-8. PubMed ID: 10185199
    [Abstract] [Full Text] [Related]

  • 4. Coverage and prior authorization of psychotropic drugs under Medicare Part D.
    Huskamp HA, Stevenson DG, Donohue JM, Newhouse JP, Keating NL.
    Psychiatr Serv; 2007 Mar; 58(3):308-10. PubMed ID: 17325102
    [Abstract] [Full Text] [Related]

  • 5. Managing prescription drug costs.
    Sica JM.
    Empl Benefits J; 2001 Mar; 26(1):35-40. PubMed ID: 11272515
    [Abstract] [Full Text] [Related]

  • 6. Engaging community mental health stakeholders in pharmacy cost management.
    Baker JG.
    Psychiatr Serv; 2001 May; 52(5):650-3. PubMed ID: 11331800
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Medicare part D and decompensation.
    Park JM, Hariprasad R, Park LT.
    Psychiatr Serv; 2006 May; 57(5):722-3. PubMed ID: 16675773
    [No Abstract] [Full Text] [Related]

  • 12. The new medicare drug benefit: formularies and their potential effects on access to medications.
    Huskamp HA, Keating NL.
    J Gen Intern Med; 2005 Jul; 20(7):662-5. PubMed ID: 16050866
    [Abstract] [Full Text] [Related]

  • 13. States' control of prescription drug spending: a heterogeneous approach.
    Morden NE, Sullivan SD.
    Health Aff (Millwood); 2005 Jul; 24(4):1032-8. PubMed ID: 16012143
    [Abstract] [Full Text] [Related]

  • 14. Mental health policy and psychotropic drugs.
    Frank RG, Conti RM, Goldman HH.
    Milbank Q; 2005 Jul; 83(2):271-98. PubMed ID: 15960772
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Do drug formulary policies reflect evidence of value?
    Neumann PJ, Lin PJ, Greenberg D, Berger M, Teutsch S, Mansley E, Weinstein MC, Rosen AB.
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.